CDKN2A and Barrett esophagus: This include hypermethylation of CDKN2A (cyclin dependent kinase inhibitor 2A) in the early phase of BE, resulting in the inactivation of CDKN2A activity, yielding it unable to stabilize tumor suppressor protein p53 or control cell cycle progression in the G1 phase [55].